Compare RH & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RH | ARQT |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2011 | 2020 |
| Metric | RH | ARQT |
|---|---|---|
| Price | $128.27 | $22.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $233.33 | $31.86 |
| AVG Volume (30 Days) | 994.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 4.84 | N/A |
| Revenue | ★ $1,193,046,000.00 | $376,072,000.00 |
| Revenue This Year | $12.43 | $34.46 |
| Revenue Next Year | $8.92 | $29.77 |
| P/E Ratio | $27.15 | ★ N/A |
| Revenue Growth | 24.52 | ★ 91.34 |
| 52 Week Low | $123.03 | $11.86 |
| 52 Week High | $264.58 | $31.77 |
| Indicator | RH | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 22.14 | 35.75 |
| Support Level | N/A | $22.56 |
| Resistance Level | $219.62 | $27.26 |
| Average True Range (ATR) | 8.33 | 1.26 |
| MACD | -3.89 | -0.26 |
| Stochastic Oscillator | 0.02 | 3.25 |
RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 24 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.